Northland Securities Reaffirms “Buy” Rating for Intrexon Corporation (XON)

Northland Securities restated their buy rating on shares of Intrexon Corporation (NYSE:XON) in a research report sent to investors on Friday. They currently have a $21.00 price target on the biotechnology company’s stock.

XON has been the subject of a number of other reports. Zacks Investment Research cut Intrexon Corporation from a hold rating to a sell rating in a research note on Thursday, July 13th. Bank of America Corporation decreased their price objective on Intrexon Corporation from $25.00 to $21.00 and set a neutral rating for the company in a research note on Friday. Stifel Nicolaus lifted their price objective on Intrexon Corporation from $39.00 to $57.00 and gave the stock a buy rating in a research note on Friday. BidaskClub cut Intrexon Corporation from a hold rating to a sell rating in a research note on Friday, August 4th. Finally, JMP Securities reaffirmed an outperform rating and set a $42.00 price objective on shares of Intrexon Corporation in a research note on Thursday, October 5th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Intrexon Corporation currently has an average rating of Hold and an average price target of $38.50.

Shares of Intrexon Corporation (NYSE:XON) opened at $11.81 on Friday. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01. Intrexon Corporation has a 52-week low of $11.80 and a 52-week high of $32.90.

WARNING: This report was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.themarketsdaily.com/2017/11/13/northland-securities-reaffirms-buy-rating-for-intrexon-corporation-xon.html.

In other Intrexon Corporation news, Director Robert B. Shapiro bought 2,850 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The stock was purchased at an average cost of $17.50 per share, with a total value of $49,875.00. Following the completion of the purchase, the director now owns 43,157 shares in the company, valued at $755,247.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 56.30% of the stock is currently owned by insiders.

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Intrexon Corporation by 3.4% during the second quarter. Vanguard Group Inc. now owns 4,433,879 shares of the biotechnology company’s stock worth $106,811,000 after buying an additional 147,517 shares during the period. State Street Corp boosted its position in shares of Intrexon Corporation by 34.0% during the first quarter. State Street Corp now owns 2,707,242 shares of the biotechnology company’s stock worth $53,664,000 after buying an additional 687,406 shares during the period. First Trust Advisors LP boosted its position in shares of Intrexon Corporation by 3.4% during the third quarter. First Trust Advisors LP now owns 1,588,779 shares of the biotechnology company’s stock worth $30,203,000 after buying an additional 51,691 shares during the period. Peregrine Capital Management LLC boosted its position in shares of Intrexon Corporation by 25.3% during the third quarter. Peregrine Capital Management LLC now owns 583,328 shares of the biotechnology company’s stock worth $11,089,000 after buying an additional 117,605 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Intrexon Corporation by 3.5% during the first quarter. Geode Capital Management LLC now owns 429,532 shares of the biotechnology company’s stock worth $8,513,000 after buying an additional 14,674 shares during the period. 77.28% of the stock is owned by institutional investors.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Analyst Recommendations for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply